NCT05578287View on ClinicalTrials.gov

RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 18, 2023

Primary Completion Date

December 15, 2024

Study Completion Date

December 25, 2025

Conditions

Colorectal Cancer

Interventions

DRUG

Anti-HER2 ADC

Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid

Trial Locations (1)

510655

RECRUITING

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors

lead

Sun Yat-sen University

OTHER